



4407

PATENT
ATTORNEY DOCKET NO. 082/US/PCT2/US-AJW
SP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EV954532792 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[X] If checked, two copies of this correspondence are enclosed.

Date of Deposit: 4-4-2007

Signature

Dawn M. MacPherson

Printed name of person mailing correspondence

Applicant:	THURIEAU, Christophe <i>et al.</i>
Serial No.:	10/771,725
Filed:	February 4, 2004
Title:	Imidazolyl Derivatives

Art Unit: 1624

Examiner: TUCKER, Zachary C.

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or
(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)

[] under 37 CFR 1.97(c) together with either:

[] a Statement under 37 CFR 1.97(e), as checked below, or

[] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[X] under 37 CFR 1.97(d) together with:

[X] a Statement under 37 CFR 1.97(e), as checked below, and

[X] a \$130.00 fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

[] Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
(Filed after payment of issue fee)

[X] All of the listed references were cited in a communication from a foreign patent office in a counterpart foreign application.

[X] Enclosed herewith is form PTO/1449 (2 pages; reproduced form), with a copy of selected references noted thereon. This application was filed after June 30, 2003 and as such, copies of any United States Patent or Patent Publications are not enclosed.

[X] Copies of the reference(s) noted on the enclosed form PTO/1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [09/719,457], to which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. 09/719,457 cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. 10/771,725.

Concise Explanation Requirement (non-English references):

[X] The "concise explanation" requirement for reference(s) [BA, BC, BE, BG, BK and BN] under 37 CFR 1.98(a)(3) is satisfied by:

[] the explanation provided on the attached sheet.

[] the explanation provided in the Specification.

[] submission of the enclosed International Search Report.

[X] the enclosed English language equivalents, translations and/or abstracts in the form of references [BB, BD, BF, BH, BL and BO] respectively.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

[X] Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.

[] No fee is believed to be due for this submission, however, Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.


[X] The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,
IPSEN (BIOMEASURE)

Dated: 4/4/07 By Pamela C. Ball
Pamela C. Ball, Agent for Applicant(s)
Registration No.: 53,963

27 Maple Street
Milford, Massachusetts 01757
Phone: (508)478-0144
Facsimile: (508) 478-2530

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
082/US/PCT2/US-AAPPLICATION NO.
10/771,725APPLICANT
THURIEAU, Christophe et al.FILING DATE
February 4, 2004GROUP/EXAMINER
TUCKER, Zachary C.

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
BA	10-502670	Mar. 10, 1998	Japan				
BB	96/16040	May 30, 1996	WIPO/PCT				
BC	10-504808	May 12, 1998	Japan				
BD	96/00730	Jan. 11, 1996	WIPO/PCT				
BE	61-024594	Feb. 3, 1986	Japan				
BF	0 166 609	Jan. 2, 1986	EP				
BG	01-203383	Aug. 16, 1989	Japan				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BH	English language abstract for JP 01-203383, published Aug. 16, 1989.
BI	AVALLONE, L. et al., "Research on heterocyclic compounds, XXXV[1]. Synthesis of 2-phenylimidazo[1,2-a]-pyrazine-3-acetates", Monatshefte fur Chemie, 1996, 127:947-953.
BJ	BARRACLOUGH, P. et al., "Synthesis and pharmacological properties of BW315C and other inotropic 2-arylimidazo[1,2-a]pyrazines", Biororganic & Med. Chem. Letters, 1993, 3:509-514.
BK	MORGENSTERN, R. et al., "Zur antihistaminischen aktivitat einiger 4-phenylimidazole". Pharmazie, 1975, 30:103-105. (in German)
BL	MORGENSTERN, R. et al., "Antihistamine activity of some 4-phenylimidazoles", Pharmazie, 1975, 30:103-105. (in English)
BM	SPITZER, W. A. et al., "Imidazo[1,2-1]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity", J. Med. Chem., 1988, 31:1590-1595.
BN	TOWLIATI, H. "Notiz uber die synthese von imidazolderivaten", Chem. Ber., 1970, 103:3952-3953. (in German)
BO	TOWLIATI, H. "Report on the synthesis of imidazole derivatives", Chem. Reports., 1970, 103:3952-3953. (English translation)
BP	WERBEL, L. M. et al., "Synthesis of fused imidazo-heterocyclic systems", J. Heterocyclic Chem., 1965, 2:287-290.

EXAMINER

DATE CONSIDERED